Tag - PRTA

Markets

BTIG ups Prothena to buy from neutral; PT $29

BTIG upgraded Prothena (NASDAQ:PRTA) to “buy” from “neutral” with a new PT of $29, citing meaningful progress of multiple clinical assets and with the potential for more promising opportunities to emerge near term. The...

February 2, 2021

Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020

Feature

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

Fueled by decades of research in protein dysregulation and fundamental neuroscience, Prothena (NASDAQ:PRTA) is advancing a pipeline of therapeutic candidates with the potential to change the course of diseases such as...

August 4, 2020

Tag - PRTA

BTIG ups Prothena to buy from neutral; PT $29

HCW starts Prothena at buy; PT $22

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

General

More